Rib-X Pharmaceuticals, Inc. to Present at the 2008 ICAAC/IDSA Joint Meeting
New Haven, Connecticut. October 20, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery, development and commercialization of
novel antibiotics for the treatment of antibiotic resistant infections, today announced
that it will present a poster entitled "A Phase 2 Study Comparing Two Doses of Radezolid to
Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)" at the 2008
ICAAC/IDSA Joint Meeting in Washington, D.C. Details on the presentation are as follows:
Poster Session: New Treatment Options in Skin and Soft Tissue Infections
Poster Title: A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)
Date: Sunday, October 26, 2008
Time 12:15pm ET - 1:15pm ET
Location: Hall C
"We are extremely proud to have been selected to present at the leading global antimicrobials conference," said Susan Froshauer, Ph.D., President and Chief Executive Officer, Rib-X Pharmaceuticals. "These data result from one of two proof-of-concept phase 2 trials with radezolid, a compound which derives from the Rib-X proprietary drug discovery approach. It is an honor to have our work recognized by the ICAAC/IDSA joint meeting organizers."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
Poster Session: New Treatment Options in Skin and Soft Tissue Infections
Poster Title: A Phase 2 Study Comparing Two Doses of Radezolid to Linezolid in Adults with Uncomplicated Skin and Skin Structure Infections (uSSSI)
Date: Sunday, October 26, 2008
Time 12:15pm ET - 1:15pm ET
Location: Hall C
"We are extremely proud to have been selected to present at the leading global antimicrobials conference," said Susan Froshauer, Ph.D., President and Chief Executive Officer, Rib-X Pharmaceuticals. "These data result from one of two proof-of-concept phase 2 trials with radezolid, a compound which derives from the Rib-X proprietary drug discovery approach. It is an honor to have our work recognized by the ICAAC/IDSA joint meeting organizers."
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product-driven small-molecule drug discovery and development company focused on developing and commercializing antibiotics to treat highly-resistant bacterial infections. Based in New Haven, Connecticut, the Company has raised over $170 million and has two programs, delafloxacin and radezolid, in advanced clinical trials. In addition, a preclinical program featuring an entirely new class of broad-spectrum antibiotics with the potential to treat even highly- resistant Gram-negative infections is scheduled to begin clinical trials in 2011.
Rib-X designs and develops novel small-molecule antibiotics by leveraging the Company's Nobel Prize- winning discovery platform to perform structure-based design and optimization. While many commercially valuable classes of antibiotics bind to the bacterial ribosome, including oxazolidinones, tetracyclines and macrolides, traditional antibiotic discovery relies heavily on serendipity. Rib-X's key competitive advantage is its proprietary understanding of ribosome structure, which enables it to generate antibiotics that overcome known resistance mechanisms and have broad-spectrum activity.
Rib-X's integrated research strategy combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, thereby allowing Rib-X to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinct new antibiotic classes.
| Public Relations |
|---|
|
Kari Watson
MacDougall BioMedical Communications 781-235-3060 kari@macbiocom.com |
| Investor Relations |
|
Sarah Cavanaugh
MacDougall BioMedical Communications 781-235-3060 scavanaugh@macbiocom.com |